Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announces that it is attending Bio€quity Europe, which takes place from 14-16 May in Ghent, Belgium.
Nexstim CEO and Chairman Martin Jamieson and CFO Mikko Karvinen will attend and participate in a series of 1-1 investor meetings at the event.
Bio€quity Europe is a life science focused investor and partnering event organised by BioCentury, now celebrating its 19th annual meeting. It has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals.
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
Further information:
Nexstim
Martin Jamieson, Chairman and CEO
+44 77 1516 3942
martin.jamieson@nexstim.com
Citigate Dewe Rogerson
David Dible/Shabnam Bashir/Isabelle Andrews
+44 (0)207 2822949
david.dible@citigatedewerogerson.com
About Nexstim Plc
Nexstim is a targeted neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.
Nexstim has launched its NBT® system in the US for the treatment of Major Depressive Disorder (MDD) following clearance from the FDA for marketing and commercial distribution for this indication.
The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the US.